Press Release

Ended the quarter with a strong cash position of $53.9 million Revenues grew 245% year-over-year to $0.8 million for the quarter Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin Well-positioned to offer psychedelic-assisted psychotherapy ... [Read]

Numinus has received approvals from Health Canada and the Institutional Ethics Review Board VANCOUVER, BC, Jan. 19, 2022 – Numinus Wellness Inc. (TSXV:NUMI)  (“Numinus” or the “Company”), a leader in psychedelics-focused mental healthcare, is pleased ... [Read]

The trial evaluates Numinus’ first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(“Numinus“), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally ... [Read]

VANCOUVER, BC, Jan. 5, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”) (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for ... [Read]

Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a ... [Read]

Numinus will ring the TSX opening bell to celebrate this milestone VANCOUVER, BC, Dec. 14, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, ... [Read]